Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
St. Jude Children's Research Hospital today announced the availability of one of the world's largest collections of leukemia samples from children and adults.
While it has long been recognized that mutated gene NPM1 plays an important role in acute myeloid leukemia, no one has determined how the normal and the mutated forms of the protein NPM1 function.
Think of energy metabolism like a party popper: Ripping something apart releases a bang. Most of your cells rip apart sugar to release the "bang" of energy. Sometimes they rip apart fats, and in a pinch, cells can even metabolize protein.
A research team led by Dr. Xiang David Li from the Department of Chemistry at The University of Hong Kong, in collaboration with scientists from Tsinghua University in China, The Rockefeller University, and The University of Texas MD Anderson Cancer Center in the United States, developed the first chemical inhibitors against a novel therapeutic target for treatment of acute myeloid leukemia, a fast-growing cancer of bone marrow and blood cells.
Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.
Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.
A cancer therapy based on fusing two types of cells into a single unit shows promise in strengthening existing treatments for acute myeloid leukemia. The approach joins blood platelets that carry cancer drugs with stem cells that guide the platelets into bone marrow where leukemia begins.
UT Southwestern scientists, working with colleagues at a sister institution in Houston, have identified a new target for battling a deadly form of leukemia.
Researchers from The Ottawa Hospital and the University of Ottawa have developed a promising targeted strategy to treat chemotherapy-resistant acute myeloid leukemia and a diagnostic test to determine which AML patients would most likely benefit from this treatment.
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., today announced detailed results from the Phase III SOLO-1 trial testing LYNPARZA (olaparib) 300 mg tablets twice-daily as a maintenance treatment for patients with newly diagnosed advanced BRCA-mutated ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.
The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias.
Physicians who specialize in a devastating and aggressive immune disorder called hemophagocytic lymphohistiocytosis report in a new study that extra care should be taken to ensure an HLH diagnosis doesn't obscure possible underlying cancers.
Lung cancer is the leading cause of cancer death among men and women. About 85 percent of lung cancers are non-small cell lung cancer. For a handful of these patients, therapies that target specific genetic mutations are effective.
It's possible to postpone the introduction of blood transfusions for an average of 17 months for patients with the low-risk variant of MDS blood cancer, provided they are given erythropoiesis-stimulating agents, which stimulate the body to produce red blood cells, according to a dissertation at Sahlgrenska Academy, Sweden.
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes.
Your body's blood cells are manufactured by hematopoietic stem cells in bone marrow. But just as regular, mature cells can become cancerous, so too can stem cells.
A group of Canadian and Korean scientists and physicians have developed the first DNA-based test that allows them to tell which patients will relapse after receiving chemotherapy and a bone marrow transplant, for their acute myeloid leukemia, or AML.
McMaster University researchers have provided evidence of new cancerous cells they have termed cancer regenerating cells, which are responsible for the return of acute myeloid leukemia after remission.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefited from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.